Rural New England Health Study (Phase 2)
Status unconfirmed · Not applicable
Conditions studied: Hepatitis C, Opioid Use Disorder, IV Drug Usage
In brief
This study will integrate mobile hepatitis C virus (HCV) testing and treatment with expanded syringe access in order to improve uptake of HCV testing and treatment, and reduce syringe sharing behavior in rural northern New England. The intervention aims to reach rural opioid injectors with HCV and to fill service gaps identified around access to syringe services and HCV testing and treatment, while limiting the burden on local partners. If effective, this mobile model of HCV telehealth integrated with syringe services will provide a promising approach for local public health authorities seeking to curb opioid injection, syringe sharing and HCV rates in rural America, and reduce the risk environment for HIV outbreaks in those communities.
Key facts
- Study ID
- NCT05466331
- Run by
- Baystate Medical Center
- People needed
- 220
- Starts
- 2022-05-18
- Expected to finish
- 2024-07-31
- Last updated by the study team
- 2023-12-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Current or past history of drug injection;
- Health insurance that will cover HCV medications (study staff will work with those who are eligible but have not signed up for insurance prior to study enrollment)
- Lives in one of the study counties in NH and VT, and plans to remain in the study region for the next 12 months;
- Age 18 years or older;
- Speaks English;
- Capacity to voluntarily provide informed consent;
- Will accept randomized assignment, and participate in follow-up over 12 months;
- Will provide releases to access community medical records;
- Will provide names and contact information of at least 3 persons for re-contact purposes;
- Not previously treated for HCV;
- Not pregnant or trying to conceive;
- HCV antibody positive on point-of-care rapid test.
You may not qualify if…
- Unable to obtain venous blood sample for mandatory laboratory testing
- HCV viral load undetectable
- Hepatitis B surface antigen (HBsAg) positive;
- Significant renal failure (eGFR 30 mL/min/1.73m2 or less, or end-stage renal disease requiring dialysis);
- Decompensated cirrhosis, as manifested by liver fibrosis on elastography (FibroScan) and/or Fibrosure blood test plus at least one of the following symptoms:
- i. Observed jaundice (yellowing of the eyes and skin) ii. Self-reported increasing abdominal size (ascites) and leg edema iii. Observed periods of confusion consistent with encephalopathy iv. Self-reported history of gastrointestinal bleeding.
Where it is running
- Mobile Study Van — Keene, New Hampshire, United States (enrolling)
- Mobile Study Van — Bennington, Vermont, United States (enrolling)
- Mobile Study Van — Brattleboro, Vermont, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.